- Buffett's Berkshire Hathaway Boosts Stake in Wal-Mart
- Time Warner to Spin Off AOL on December 9
- Gates Boosts Waste Management, Coca Cola Stakes
- What's Kept Stock Rally Going? Fear, Not Confidence
- Fed to Keep Rates Low Despite Dollar's Fall: Bernanke
- Citi Shares, A Strange Indicator Of Unemployment?
- Millions Could Have to Repay Part of Obama's Tax Credit
- Hollywood Turns to Porn as Unemployment Rises
- Slideshow: US Cities With Most Underwater Mortgages
- Answers to Your Questions: A Path to Economic Disaster?
- 5 Ways to Play the Chinese Markets: Analyst
- Meredith Whitney: Turns Bearish
- 3 Stock Plays on Rising College Costs
- Warren Buffett's Berkshire Hathaway Almost Doubles Wal-Mart Holdings During Summer
- Nov. 16: Unusual Volume Leaders
- Getting to the Heart of the Merck-Abbott Embargo Break
- What MGM's Sale Could Say About Value of Content
- My Ratings on Lowe's & Home Depot: Analyst
MOST SHARED
- Stocks Overvalued, Recession Will Return: Meredith Whitney
- Has Twitter's Finest Hours (Seconds) Come and Gone?
- U.S. May Wind Up Green With Envy
- BofA Ex-Counsel: I Was 'Stunned' When I Got Fired
- Bernanke Offers Something For Everyone
- Fed Likely to Keep Rates Low Despite Dollar's Fall: Bernanke
- Solar Emerges From A Dark Period
- Oil Tomorrow
- Stanford Receiver to Release Funds Of Frozen Acounts
- Warren Buffett's Berkshire Hathaway Almost Doubles Wal-Mart Holdings During Summer
Text Size 
Medical-testing company Quest Diagnostics [DGX
Loading...
()
]
AmeriPath, controlled by Welsh, Carson, Anderson and Stowe IX L.P., provides dermatopathology, anatomic pathology and esoteric testing and has annual revenue of more than $800 million.
The total deal value, including about $770 million in assumed debt, comes to $2 billion, the companies said. Welsh, Carson had acquired AmeriPath in 2003 for $627 million.
Shares of Quest fell about 4% Monday. Analysts said investors were disappointed by the high price paid for a company that has struggled with tough competition, as well as disappointment that the acquisition may reduce the possibility that Quest may be taken private in a leveraged buyout.
"Our early view is negative, given (that) both AmeriPath and Specialty Laboratories, which was consolidated with AmeriPath, struggled as public companies," said Bank of America analyst Robert Willoughby.
"Competitors, including Quest Diagnostics and LabCorp of America, successfully made inroads into Specialty Laboratories' market share, contributing to disappointing organic growth," Willoughby said.
AmeriPath, which grew through multiple acquisitions, operates three divisions. Its Dermpath Diagnostics business has more than 80 dermatopathologists who interpret 2.4 million biopsies annually. Its anatomic pathology division focuses on gastroenterology, urology, oncology and women's health. Specialty Laboratories is a full-service clinical lab serving hospitals and physicians.
Quest said the deal would accelerate its revenue and earnings growth. The acquisition is expected to have minimal impact on Quest Diagnostics' 2007 earnings per share and mostly boost earnings in 2008, excluding deal-related charges.
"The deal appears to us to be a response to the lost (United Healthcare) deal," said Willoughby, referring to Quest's loss of a key insurance customer contract last year that accounted for about 7% of Quest's annual revenue.
The acquisition "ties up capital better deployed on small pathology and other services acquisitions that would position it better with managed care payers for more sustainable, capital efficient growth," Willoughby said.
Quest said it plans to pay for the transaction, refinance AmeriPath's existing debt, and the debt from the HemoCue acquisition completed earlier this year with the proceeds of a new $1 billion one-year bridge loan and a new five-year $1.5 billion term loan.
Print
Email
- Where, what, how.
- CNBC's Jim Goldman asks: Has the sun begun to set on Twitter? Data suggests its best days are over.
- Everyone wanted a piece of Madoff's "Bullship"--the famous buoy sold for $7,500 at auction. You won't believe these prices.
- De Loach Vineyards is selling its pinot noir the old fashioned way, helping to cut energy and transportation costs.
- Why are the Chinese concerned about the progress of U.S. health care legislation?
- CNBC's Maria Bartiromo talks to rapper Snoop Dogg about brand identity in both business and music.
Data is a real-time snapshot *Data is delayed at least 15 minutes